Vivoryon Therapeutics N.V. Shares Clinical Development Update Highlighting Progress of N3pE-Amyloid-targeting Small Molecule Varoglutamstat in Alzheimer’s Disease
July 16, 2023 03:00 ET
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. Shares Clinical Development Update Highlighting Progress of N3pE-Amyloid-targeting Small Molecule Varoglutamstat in Alzheimer’s Disease Small molecule varoglutamstat,...
Vivoryon Therapeutics N.V. Reports Outcome of 2023 Annual General Meeting
June 21, 2023 12:02 ET
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. Reports Outcome of 2023 Annual General Meeting All proposed resolutions approvedElection of two new Non-Executive Board members Halle (Saale) / Munich, Germany, June...
Vivoryon Therapeutics N.V. Announces CEO Transition Plan
June 15, 2023 11:49 ET
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. Announces CEO Transition Plan Dr. Ulrich Dauer not to extend current term running through 2024 AGMBoard to initiate succession planning Halle (Saale) / Munich,...
Vivoryon Therapeutics N.V. to Participate in Upcoming Conferences
June 01, 2023 01:00 ET
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. to Participate in Upcoming Conferences Halle (Saale) / Munich, Germany, June 1, 2023 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a...
Vivoryon Therapeutics Successfully Completes Private Placement Raising EUR 25 Million
May 26, 2023 01:39 ET
|
Vivoryon Therapeutics N.V.
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA OR ANY OTHER JURISDICTION...
Vivoryon Therapeutics Launches Capital Increase by Way of an Accelerated Bookbuild Offering
May 25, 2023 11:50 ET
|
Vivoryon Therapeutics N.V.
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA OR ANY OTHER JURISDICTION...
Vivoryon Therapeutics N.V. Reports Q1 2023 Financial Results and Highlights Operational Progress
May 16, 2023 01:00 ET
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. Reports Q1 2023 Financial Results and Highlights Operational Progress Halle (Saale) / Munich, Germany, May 16, 2023 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY;...
Vivoryon Therapeutics N.V. to Hold its 2023 Annual General Meeting on June 21, 2023
May 09, 2023 01:02 ET
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. to Hold its 2023 Annual General Meeting on June 21, 2023 Halle (Saale) / Munich, Germany, May 9, 2023 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY;...
Vivoryon Therapeutics N.V. to Report Q1 2023 Financial Results and Operational Progress on May 16, 2023
May 09, 2023 01:00 ET
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. to Report Q1 2023 Financial Results and Operational Progress on May 16, 2023 Halle (Saale) / Munich, Germany, May 9, 2023 – Vivoryon Therapeutics N.V. (Euronext...
Vivoryon Therapeutics N.V. Announces Planned Changes to Board Composition at 2023 Annual General Meeting
May 01, 2023 04:00 ET
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. Announces Planned Changes to Board Composition at 2023 Annual General Meeting Halle (Saale) / Munich, Germany, May 1, 2023 – Vivoryon Therapeutics N.V. (Euronext...